Budesonide capsules: Scientific basis

Drugs of Today

Volumn 36, Issue SUPPL. G, 2000, Pages 9-23

  Edsbacker, S ^a   Sachar, ^a   Pena, ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID RECEPTOR; CYTOKINE; DESOLETT; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; METHYLPREDNISOLONE; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; TRIAMCINOLONE ACETONIDE;

ASTHMA; CHRONOTHERAPY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG INACTIVATION; DRUG POTENCY; DRUG RETENTION; DRUG SELECTIVITY; ENTERITIS; HUMAN; LIVER METABOLISM; REMISSION; RHINITIS; RISK BENEFIT ANALYSIS;

EID: 0033674694     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Clinical course and costs of care for Crohn's disease. Markov model analysis of a population-based cohort
2. Clinical patterns in Crohn's disease. A statistical study of 615 cases
3. National Cooperative Crohn's Disease Study; results of drug treatment
4. European Cooperative Crohn's Disease Study (ECCDS); results of drug treatment
5. Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease
6. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies
7. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
8. Budesonide; an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis
9. Budesonide - A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease
10. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man
11. Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids
12. The clinical efficacy of budesonide in hay fever is dependent on topical nasal application
13. A study of the mechanism of the antiasthmatic action of inhaled budesonide
14. How often is medication taken as prescribed? A novel assessment technique
15. Improving patient compliance: A guide for physicians
16. Targeted drug delivery in treatment of intestinal diseases
17. A budesonide prodrug accelerates treatment of colitis in rats
18. Have steroids a future in Crohn's disease?
19. Oral fluticasone and prednisolone in treatment of active Crohn's disease - A randomised double-blind multicentre study
20. Rectal pharmacokinetics of budesonide
21. Intraluminal concentrations of budesonide following administration of Entocort capsules in subjects with ileostomy
22. Ileocolonic transit does not change after right hemicolectomy
23. Food does not alter site of absorption of budesonide from controlled ileal release capsules
24. Autonomous telemetric capsule to explore the small bowel
25. Uptake of budesonide from ileum, cecum, and proximal colon studied by means of an intestinal telemetric remote-release capsule
26. Mucosal uptake and retention of steroids in rat ileum: Possible explanation of topical efficacy in inflammatory bowel disease
27. Onset of action and topical antiinflammatory efficacy of budesonide in allergen challenged rat ileum
28. A comparison of the fatty acid esters of estradiol and corticosterone synthesized by tissues of the rat
29. Steroidal fatty acid esters
30. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes
31. The prolonged activity of a budesonide pulse depends on its reversible intracellular esterification - Studied in vitro
32. High capacity of airway/lung tissue for budesonide esterification as compared to peripheral striated muscles
33. Immunopharmacology of budesonide induced inhibition of pro-inflammatory cytokine secretion by IBD mononuclear phagocytes
34. (The Global Budesonide Study Group): Oral budesonide is as effective as oral prednisolone inactive Crohn's disease
35. Clinical PK/PD modelling as a tool in drug development of corticosteroids
36. Budesonide is metabolized by cytochrome-P450 3A (CYP3A) enzymes in human liver
37. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol
38. Effect of food on budesonide pharmacokinetics in patients with active Crohn's disease
39. Pharmacological factors that influence the choice of inhaled corticosteroids
40. Dose-proportional kinetics of budesonide controlled ileal release capsules
41. Pharmacokinetics of budesonide controlled ileal release capsules in active Crohn's disease
42. Budesonide CIR capsules in children and adults with Crohn's disease. A pharmacokinetic and tolerability study
43. Pharmacokinetics of budesonide in children with asthma
44. Reduced inhibitory effect of ketokonazole on budesonide pharmacokinetics by separating their time of administration
45. Budesonide pharmacokinetics is not affected by omeprazole
46. A comparison of budesonide with prednisolone for active Crohn's disease
47. A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone
48. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease
49. Oral budesonide for treatment of autoimmune chronic active hepatitis
50. Budesonide for the treatment of collagenous colitis: First results of a pilot trial
51. Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology